Titan Pharmaceuticals, Inc. (TTNP) News

Titan Pharmaceuticals, Inc. (TTNP): $0.53

-0.03 (-4.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TTNP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

Filter TTNP News Items

TTNP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest TTNP News From Around the Web

Below are the latest news stories about Titan Pharmaceuticals Inc that investors may wish to consider to help them evaluate TTNP as an investment opportunity.

Titan Pharmaceuticals Raises $5.5M Via Equity

Titan Pharmaceuticals Inc (NASDAQ: TTNP ) has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. In addition, the Company has agreed to issue to the investor unregistered warrants to purchase up to an aggregate of 4.67 million shares. The combined offering price of each share or pre-funded warrant and Full story available on Benzinga.com

Benzinga | February 2, 2022

Titan Pharmaceuticals to raise $5.5M in stock and pre-funded warrant offering

Titan Pharmaceuticals (TTNP) trades 3.9% lower premarket after it entered into a securities purchase agreement with a single institutional investor to purchase 3.37M shares in a

Seeking Alpha | February 2, 2022

Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in th

Yahoo | February 2, 2022

Vericel (NASDAQ:VCEL) versus Titan Pharmaceuticals (NASDAQ:TTNP) Critical Review

Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Profitability This table compares Titan Pharmaceuticals and Vericels net margins, return on equity and return on []

Transcript Daily | December 24, 2021

Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Shares Rebounded 9.65% From Their Lows But Can They Continue?

In last trading session, Titan Pharmaceuticals Inc. (NASDAQ:TTNP) saw 0.69 million shares changing hands with its beta currently measuring 0.78. Companys recent per share price level of $1.14 trading at -$0.11 or -8.80% at ring of the bell on the day assigns it a market valuation of $11.19M. That closing price of TTNPs stock is Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Shares Rebounded 9.65% From Their Lows But Can They Continue? Read More »

Marketing Sentinel | December 24, 2021

Comparing Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL)

Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Profitability This table compares Titan Pharmaceuticals and Vericels net margins, return on equity and return on [] The post Comparing Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) appeared first on ETF Daily News .

ETF Daily News | December 22, 2021

Titan Pharmaceuticals to Explore Strategic Alternatives

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Titan has engaged Maxim Group LLC as its exclusive financial advisor to assist in this process.

Yahoo | December 21, 2021

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Down 19.7% in November

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 336,900 shares, a decline of 19.7% from the November 15th total of 419,700 shares. Based on an average daily volume of 183,400 shares, the short-interest ratio is presently 1.8 days. []

Transcript Daily | December 20, 2021

Head to Head Contrast: Vericel (NASDAQ:VCEL) & Titan Pharmaceuticals (NASDAQ:TTNP)

Vericel (NASDAQ:VCEL) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk. Profitability This table compares Vericel and Titan Pharmaceuticals net margins, return on equity and return on []

Dakota Financial News | December 17, 2021

U.S. Opioids Market Huge Growth in Future Scope 2021-2028 | Purdue Pharma L.P., Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH

"U.S. Opioids Market, Drug Price, Sales and Clinical Trials Insight 2028 Report Highlights: U.S. Opioids Market Opportunity: > US$ 18,985.4 Million by 2028 U.S. Opioids Market Growth: 100% Absolute Growth Till 2028 U.S. Opioids Market Size Opportunity by Therapeutic Class Insight On Clinical

OpenPR | December 3, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4663 seconds.